Biosergen AB will be delisted from Nasdaq First North on October 22, 2026, as the company completes its merger with Flerie AB, with shareholders set to receive new Flerie shares by October 28.
Biosergen is set to be dissolved and delisted from the Nasdaq First North Growth Market following the Swedish Companies Registration Office's (Bolagsverket) approval of its merger with Flerie AB. Shareholders will receive Flerie shares as merger consideration, with the final day of trading for Biosergen stock expected to be October 22, 2026.
Shareholders will receive one (1) new common share in Flerie for every thirty-one (31) shares held in Biosergen.
No, no action is required by Biosergen shareholders to receive the merger consideration.
Flerie AB is the acquiring entity in the merger with Biosergen, which will result in the absorption of all Biosergen's assets and liabilities. Following the merger, Biosergen's operations will be transferred to a new subsidiary under Flerie Invest AB, with Flerie issuing new shares to compensate Biosergen shareholders.
The merger consideration is expected to be distributed to eligible shareholders around October 28, 2026.
No, trading in Flerie's shares will continue as usual and will not be affected by the merger process.
The Swedish Companies Registration Office has approved the merger between Flerie AB and Biosergen AB. Biosergen will be dissolved and delisted from Nasdaq First North on October 22, 2026, with shareholders receiving Flerie shares at a ratio of 1:31.
Biosergen will be dissolved and delisted. Shareholders will automatically receive one new Flerie share for every 31 shares held in Biosergen, with no action required from the investor.